Abstract
Background: Five-year overall survival (OS) for resected pancreatic ductal adenocarcinoma (PDAC) remains poor at 16.3%. In clinical stage (CS) I-II PDAC, CA19-9 levels < 98U/mL portend a favorable prognosis, while surgical resection improves survival irrespective of CA19-9 levels. Currently, 40% of patients with PDAC are unable to complete adjuvant therapy. We evaluated the role of therapy for early-stage resectable PDAC based on pre-operative CA19-9 levels.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
